Novel targeted therapeutic approaches like the anti-IFN-γ monoclonal antibody, JAK1/2 inhibitor which is shown to be effective in primary HLH (51, 52) can be considered in patients with FA especially with elevated cytokine levels. Here, JAK1 is linked to hemophagocytic syndrome.